▽PKC412 - PubMed - NCBI ●01/08 11:32 78CiteSharePKC412 normalizes mutation-related keratin filament disruption and hepatic injury in mice by promoting keratin-myosin binding.Kwan R, Chen L, Looi K, Tao GZ, Weerasinghe SV, Snider NT, Conti MA, Adelstein RS, Xie Q, Omary MB. Kwan R, et al. Hepatology. 2015 Dec;62(6):1858-69. doi: 10.1002/hep.27965. Epub 2015 Aug 25. Hepatology. 2015. PMID: 26126491 Free PMC article.Furthermore, P
▽temsirolimus - PubMed - NCBI ●01/08 10:31 A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer.Aghajanian C, Filiaci V, Dizon DS, Carlson JW, Powell MA, Secord AA, Tewari KS, Bender DP, O'Malley DM, Stuckey A, Gao J, Dao F, Soslow RA, Lankes HA, Moore K, Levine DA. Aghajanian C, et al. Gynecol Oncol. 2018 Aug;
▽AME-133v - PubMed - NCBI ●01/08 10:22 The future of CD20 monoclonal antibody therapy in B-cell malignancies.Czuczman MS, Gregory SA. Czuczman MS, et al. Leuk Lymphoma. 2010 Jun;51(6):983-94. doi: 10.3109/10428191003717746. Leuk Lymphoma. 2010. PMID: 20367564 Review.Preclinical and early clinical assessment of other novel anti-CD20 mAbs include: ocrelizumab, veltuzumab, GA101, AME-133v, and PRO131921; data suggest potential for impro
▽fostamatinib - PubMed - NCBI ●01/08 10:02 Gefitinib and fostamatinib target EGFR and SYK to attenuate silicosis: a multi-omics study with drug exploration.Wang M, Zhang Z, Liu J, Song M, Zhang T, Chen Y, Hu H, Yang P, Li B, Song X, Pang J, Xing Y, Cao Z, Guo W, Yang H, Wang J, Yang J, Wang C. Wang M, et al. Signal Transduct Target Ther. 2022 May 13;7(1):157. doi: 10.1038/s41392-022-00959-3. Signal Transduct Target Ther. 2022. PMID: 35551
